TUC-S.R.L.
Just over a month after the Digital World Premiere, TUC.tiny is ready to make its debut at VivaTech 2024, the most important technology fair in Europe. In Hall 1, Pavilion 41, TUC S.r.l. will present to the public for the first time its latest technological innovation: TUC.tiny®, the Modular Dashboard concept, and the TUC.technology offering, developed to revolutionize the world of mobility.
TUC.tiny® is the compact version of the industrialized technology launched last year, based on the TUC.technology® patent and released in over 140 countries. It is currently the subject of collaborations with industry leaders such as ZER01NE, the Hyundai Motor Group's Open Innovation Platform, for the development of "Human-centric" vehicles.
This technological gem is based on the three pillars of TUC: mechanical structure, electronic management, and data exchange. Thanks to the integration of USB Type-C technology, TUC.tiny® aims to reinvent the interaction between users and vehicles, converging mobility and everyday life.
The result of advanced research by TUC S.r.l. in technological miniaturization and simplification, TUC.tiny® represents the core of the company's patented technology, designed to innovate the value chain in the mobility sector with a "human-centric" approach. It is an ideal solution for both the main players in the sector and users, representing a perfect synthesis of their needs.
The Modular Dashboard, developed to showcase the potential of TUC.tiny®, is a true blank canvas, customizable infinite times thanks to TUC.tiny® and TUC.technology®. An environment to inhabit and configure without limits, adapting functionally and flexibly to the needs of users.
With TUC.tiny® and its advanced interface - including physical fastening, electrical connectivity, and data transfer - any device can be integrated into the modular dashboard design, making it immediately operational. TUC.tiny® supports all everyday devices with USB Type-C connection, distinguishing itself by seamlessly blending into any part of the vehicle. Its robustness is ensured by a mechanical or electro-actuated locking mechanism, introducing the novelty of NFC technology for added security.
The introduction of TUC.tiny® completes the TUC.technology® offering, marking a step forward towards the democratization of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives.
TUC.tiny® and TUC.technology® embody the vision of the mobility ecosystem of the future: interconnected, multimodal, circular, and dynamic. This technology not only connects but synthesizes different spheres of our lives, making mobility more accessible, customizable, and environmentally conscious.
TUC invites everyone to imagine and build together a world where technology unites us, improving every aspect of our daily journey. The project, which started in the automotive sector, now aims to scale the technology to new verticals such as aerospace and marine sectors.
“The World Premiere of TUC.tiny® at VivaTech 2024 is an important recognition for TUC.technology as an enabler of the Mobility of the Future," said Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny® represents our promise for the future: the vision of a world where technology and mobility create personalized experiences designed around the needs of each individual. This is the future that TUC S.r.l. is building: a mobility ecosystem driven by the values of democratization, personalization, and sustainability."
TUC.tiny® and the Modular Dashboard are ready to be showcased live to the public at VivaTech 2024, demonstrating that this vision is already a reality.
For more information, visit the "NEWSROOM" section of the website: https://www.tuc.technology/newsroom.
ABOUT TUC.technology
TUC S.r.l. is a leading Deep-Tech company in mobility innovation, specializing in the development of modular solutions for vehicles that aim to simplify and revolutionize the concept of a vehicle. Distinguished by technological excellence on an international level, TUC has received significant recognitions, including exhibitions at CES in Las Vegas and the National Automobile Museum.
With the launch of TUC 3.0, the company sets new standards in the sector, collaborating with major global OEMs. Learn more at http://www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515972855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom